Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
Clinical trial Global

Thymosin beta-4 eye drop RGN-259 enters two simultaneous phase 3 trials in neurotrophic keratitis

RegeneRx says on its RGN-259 page that its U.S. joint venture ReGenTree LLC has initiated phase 3 trials in the U.S. and EU of RGN-259, an eye drop based on thymosin beta-4, in neurotrophic keratitis, with initial results targeted for early 2024, after top line results from the first phase 3 trial (SEER-1) were reported in May 2020.

Sterile preservative-free single-use eye drop vials on a clinical laboratory bench

What is thymosin Beta-4 (TB4)?

Thymosin Beta-4 (TB4) is a naturally occurring 43-amino-acid peptide (MW ~4,963 Da) found in nearly all human cells except red blood cells, where it is the principal G-actin-sequestering protein.

Read the full guide →

In 30 seconds

  • In SEER-1, 6 out of 10 patients in the RGN-259 treated group and 1 out of 8 patients in the placebo treated group achieved complete corneal healing in 4 weeks.
  • On that primary endpoint the difference was slightly over 0.05 (p = 0.0656, Fisher's exact test), while a Chi square test on the same endpoint gave p = 0.0400.
  • Two confirmatory trials, SEER-2 and SEER-3, are being run at the same time in approximately 70 neurotrophic keratitis patients each, with complete corneal healing as the primary endpoint.

Why it matters

The company describes RGN-259 as a sterile and preservative-free eye drop based on thymosin beta-4, and calls it its highest priority. It is being developed for dry eye disease and for neurotrophic keratitis (NK), which the company describes as a persistent corneal defect caused by diabetes and the herpes zoster virus, among other pathologies. NK is an orphan disease, as there are fewer than 200,000 cases in the U.S., and RegeneRx says it previously received orphan drug status from the U.S. FDA for RGN-259 in NK. Readers following the molecule itself can see our thymosin beta-4 guide.

The details

  • SEER-1 (first phase 3 in NK): double-masked and placebo-controlled, it recruited, treated and analysed 18 patients, and top line results were reported in May 2020.
  • Healing: 6 out of 10 patients in the RGN-259 treated group and 1 out of 8 patients in the placebo treated group achieved complete corneal healing in 4 weeks.
  • Primary endpoint: on the ratio of corneal wound healed patients after four weeks' administration, the statistical difference was slightly over 0.05 (p = 0.0656, Fisher's exact test), which the company attributes to the limited number of patients in each group; a Chi square test on the same endpoint gave statistical significance, p = 0.0400.
  • Secondary endpoint: on a pre-specified secondary endpoint evaluating corneal epithelial healing at day 43 (two weeks post-treatment) and the durability of treatment, the company reports a clear statistical difference using Fisher's exact test, p = 0.0359.
  • Safety in SEER-1: the company states it was well-tolerated and that there were no safety issues.
  • SEER-2 and SEER-3: double-masked and placebo-controlled, giving RGN-259 or placebo eye drops for four weeks to approximately 70 NK patients in each trial, with a primary endpoint of complete corneal healing. ReGenTree says it aims to significantly shorten the clinical development period by running the two trials simultaneously rather than sequentially, and has recruited over 30 clinical centers, with 13 currently active in the U.S.
  • Earlier compassionate use: under a Compassionate Use IND, one physician treated 4 patients for 28 days and 2 additional patients for 49 days; the eye ulcers either completely healed or showed significant improvement by the end of treatment or shortly thereafter, and patients remained healed during the 30-day follow-up period even though the treatment regimen had been completed.
  • Dry eye disease: the ARISE programme is a series of three phase 3 trials in over 1,600 patients across multiple U.S. medical centers. The pre-specified co-primary endpoints were not met with statistical significance, but the company reports statistically significant improvements with RGN-259 compared to placebo in ocular grittiness in ARISE-3 at one week and at two weeks, including after patients were stressed in the CAE model and on several questions of the ocular surface disease index scale. Outside the pre-specified endpoints, statistically significant differences in central corneal fluorescein staining were seen at two weeks in a subpopulation of ARISE-3 patients and in a pooled sub-population of all three trials, and in inferior corneal fluorescein staining at two weeks in ARISE-2 and in the same patient population within the pooled group.
  • Context given by the company: NK is described as a relatively large market opportunity for a rare disease, with about 20,000 patients a year in the United States, and Oxervate is described as currently the only approved treatment for NK in the United States and one of the most expensive pharmacy drugs in the U.S., with a retail price of $48,498 per month for a two-month treatment course, according to industry newsletters.

What it does not change

This is not an approval. RGN-259 remains in phase 3 development, and the company itself frames SEER-2 and SEER-3 as trials designed to confirm previous phase 3 results. The SEER-1 primary endpoint did not reach p below 0.05 on the Fisher's exact test, and the company's statement that the trend likely would have reached a statistically significant p value had more patients been entered is an interpretation, not a trial result. On the dry eye side, the pre-specified co-primary endpoints of the ARISE trials were not met with statistical significance, and several of the positive findings cited are in subpopulations, in pooled data or outside the pre-specified endpoints. Further phase 3 work in dry eye has not started: the company says the goal is to await the results of the phase 3 NK trials before initiating further phase 3 trials in patients with DED.

What's next

The company says initial results for the NK programme are targeted for early 2024, with SEER-2 and SEER-3 run at the same time to shorten development, and patient recruitment supported by over 30 clinical centers, 13 of them currently active in the U.S. For dry eye disease, the joint venture intends to continue development of RGN-259 as soon as it successfully completes the phase 3 NK clinical trials.

What we don't know yet

The source page does not give results for SEER-2 or SEER-3, so the healing rates and p-values from the confirmatory trials are not known from it. It also gives no regulatory filing or submission timeline for NK or for dry eye disease, no breakdown of enrolment actually reached in each confirmatory trial, and no date for the page itself, so how current the stated targets are cannot be judged from the source. Which specific dry eye patient populations would be chosen for any future phase 3 trial is also not stated.

Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.

Source documents

This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.